Go Pro
NASDAQ:FEMY

Femasys Q2 2026 Earnings Report

Femasys logo
$2.96 +0.23 (+8.42%)
As of 08/21/2026 04:00 PM Eastern

Femasys EPS Results

Actual EPS
-$1.33
Consensus EPS
-$1.31
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.33 million
Expected Revenue
$0.73 million
Beat/Miss
Missed by -$399.17 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Friday, August 14, 2026
Conference Call Time
7:00AM ET

Femasys Earnings Headlines

Femasys (NASDAQ:FEMY) Downgraded to Sell Rating by Wall Street Zen
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
Lake Street Capital Lowers Femasys (NASDAQ:FEMY) Price Target to $10.00
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools.

Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.

View Femasys Profile